
A recent study examined receptor-binding domain (RBD)-specific and pseudovirus-neutralizing antibodies in two trials with low-dose and high-dose groups. The results showed that the two-dose regimen increased neutralizing antibody levels compared to the one-dose regimen at day 28. However, the response of neutralizing antibodies did not align with RBD antibodies. Antibody half-lives were longer with the two-dose regimen, suggesting slower decay. Positive rates varied between the regimens. The study concluded that the two-dose Ad5-nCoV regimen did not affect neutralizing antibody persistence but slowed the decline of RBD-binding antibodies.
Like
Save
Share